Multiple endocrine neoplasia type 1: a review of current diagnostic and treatment approaches

References

• Thakker RV, Newey PJ, Walls GV, et al. Endocrine society. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990–3011.
   PubMed Web of Science ®Google Scholar
• National Library of Medicine. National Center for Biotechnology Information (NCBI); PubMed.gov website. [cited 2020 May]. https://pubmed.ncbi.nlm.nih.gov/
   Google Scholar
• Online Mendelian Inheritance in Man (OMIM®). website; cited 2020 Aug 7. (Access date: May 2020). https://www.omim.org/entry/131100?search=MEN1&highlight=men1
   Google Scholar
• Giusti F, Marini F, Brandi ML Multiple Endocrine Neoplasia Type 1. GeneReviews® [Internet], initial posting: August 31, 2005; cited 2017 Dec 14. (Access date: May 2020). https://www.ncbi.nlm.nih.gov/books/NBK1538/
   Google Scholar
• Orphanet, the portal for rare diseases and orphan drugs. Orphanet version 5.39.0 - Last updated: 2020-08-10; [cited 2020 May]. https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=121&Disease_Disease_Search_diseaseGroup=MEN1&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Multiple-endocrine-neoplasia-type-1&title=Multiple%20endocrine%20neoplasia%20type%201&search=Disease_Search_Simple
   Google Scholar
• Tonelli F, Giudici F, Cavalli T, et al. Surgical approach in patients with hyperparathyroidism in multiple endocrine neoplasia type 1: total versus partial parathyroidectomy. Clinics (Sao Paulo). 2012;67(Suppl1):155–160.
   PubMedGoogle Scholar
• Arnalsteen L 1, Proye C. [Surgery of hyperparathyroidism and of its potential recurrence in the MEN I setting] [Article in French]. Ann Chir. 2003;128(10):706–709.
   PubMedGoogle Scholar
• d’Alessandro AF, Montenegro FL, Brandão LG, et al. Supernumerary parathyroid glands in hyperparathyroidism associated with multiple endocrine neoplasia type 1. Rev Assoc Med Bras. 1992;58(3):323–327.
   Google Scholar
• Lamas C, Navarro E, Casterás A, et al. MEN1-associated primary hyperparathyroidism in the Spanish Registry: clinical characteristics and surgical outcomes. Endocr Connect. 2019;8(10):1416–1424.
   PubMed Web of Science ®Google Scholar
• Nilubol N, Weisbrod AB, Weinstein LS, et al. Utility of intraoperative parathyroid hormone monitoring in patients with multiple endocrine neoplasia type 1-associated primary hyperparathyroidism undergoing initial parathyroidectomy. World J Surg. 2013;37:1966–1972.
   PubMed Web of Science ®Google Scholar
• Singh Ospina N, Thompson GB, Lee RA, et al. Safety and efficacy of percutaneous parathyroid ethanol ablation in patients with recurrent primary hyperparathyroidism and multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 2015;100:E87–90.
   PubMed Web of Science ®Google Scholar
• Del Prete M, Marotta V, Ramundo V, et al. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1. Minerva Endocrinol. 2013;38(4):389–394.
   PubMed Web of Science ®Google Scholar
• Moyes VJ, Monson JP, Chew SL, et al. Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism. Int J Endocrinol. 2010;906163:2010.
   Google Scholar
• Giusti F, Cianferotti L, Gronchi G, et al. Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1). Endocrine. 2016;52(3):495–506.
   PubMed Web of Science ®Google Scholar
• Norton JA, Krampitz G, Jensen RT. Multiple Endocrine Neoplasia: genetics and Clinical Management. Surg Oncol Clin N Am. 2015;24:795–832.
   PubMed Web of Science ®Google Scholar
• Nell S, Conemans EB, de Laat JM, et al. Liver metastases of MEN1 related duodenopancreatic neuro-endocrine tumors; strategies and outcomes. [Only abstract]. HPB. 2016;18(S1):e61.
   Google Scholar
• Polhamus A Life expectancy low in MEN1 duodenopancreatic neuroendocrine tumor liver metastases. [Internet] 2017 Mar 14; [cited 2020 May]. https://www.healio.com/news/endocrinology/20170314/life-expectancy-low-in-men1-duodenopancreatic-neuroendocrine-tumor-liver-metastases
   Google Scholar
• Yates CJ, Newey PJ, Thakker RV. Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1. Lancet Diabetes Endocrinol. 2015;3:895–905.
   PubMed Web of Science ®Google Scholar
• Sakurai A, Yamazaki M, Suzuki S, et al. Clinical features of insulinoma in patients with multiple endocrine neoplasia type 1: analysis of the database of the MEN Consortium of Japan. Endocrine J. 2012;59:859–866.
   PubMed Web of Science ®Google Scholar
• Tonelli F, Giudici F, Giusti F, et al. Gastroenteropancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. Cancers (Basel). 2012;4(2):504–522.
   PubMedGoogle Scholar
• Economopoulos P, Christopoulos C. Glucagonoma. Ann Gastroenterol. 2001;14:99–108.
   Google Scholar
• Metz DC, Cadiot G, Poitras P, et al. Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing. Int J Endocr Oncol. 2017;4(4):167–185.
   PubMed Web of Science ®Google Scholar
• van Treijen MJC, van Beek DJ, van Leeuwaarde RS, et al. Diagnosing Nonfunctional Pancreatic NETs in MEN1: the Evidence Base. J Endocr Soc. 2018;2(9):1067–1088.
   PubMed Web of Science ®Google Scholar
• Barbe C, Murat A, Dupas B, et al. Magnetic resonance imaging versus endoscopic ultrasonography for the detection of pancreatic tumours in multiple endocrine neoplasia type 1. Dig Liver Dis. 2012;44(3):228–234.
   PubMedGoogle Scholar
• Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24(4):389–427.
   PubMed Web of Science ®Google Scholar
• Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-DPhe1] and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–731.
   PubMedGoogle Scholar
• Kowalski J, Henze M, Schuhmacher J, et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003;5(1):42–48.
   PubMedGoogle Scholar
• Ito T, Jensen RT. Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies. Int J Endocr Oncol. 2016;3(1):53–66.
   PubMed Web of Science ®Google Scholar
• Morgat C, Vélayoudom-Céphise FL, Schwartz P, et al. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1. Eur J Nucl Med Mol Imaging. 2016;43(7):1258–1266.
   PubMed Web of Science ®Google Scholar
• Jullien M, Reichert T, D’Anella P, et al. Comparison of 68Ga-Dotatate PET/CT and 18F-FDOPA PET/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient. Ann Endocrinol (Paris). 2020;81(1):39–43.
   PubMed Web of Science ®Google Scholar
• Monazzam A, Lau J, Velikyan I, et al. Increased Expression of GLP-1R in Proliferating Islets of Men1 Mice is Detectable by [68 Ga]Ga-DO3A-VS-Cys 40-Exendin-4/PET. Sci Rep. 2018;8(1):748.
   PubMedGoogle Scholar
• Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30:781–793.
   PubMed Web of Science ®Google Scholar
• Falconi M, Eriksson B, Kaltsas G, et al. Vienna Consensus Conference participants 2016 ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103:153–171.
   PubMed Web of Science ®Google Scholar
• Vinault S, Mariet A-S, Le Bras M, et al. Metastatic Potential and survival of duodenal and pancreatic tumors in multiple endocrine neoplasia type 1: a GTE and AFCE cohort study (Groupe d’étude des tumeurs endocrines and association francophone de chirurgie endocrinienne). 2018 Dec 21. Online ahead of print. doi: 10.1097/SLA.0000000000003162.
   Google Scholar
• Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med. 1998;243:495–500.
   PubMed Web of Science ®Google Scholar
• Tonelli F, Marini F, Giusti F, et al. Gastro-entero-pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: a therapy update. Int J Endocr Oncol. 2017;4(1):43–58.
   Web of Science ®Google Scholar
• Tomassetti P, Migliori M, Caletti GC, et al. Treatment of Type II Gastric Carcinoid Tumors with Somatostatin Analogues. N Engl J Med. 2000;343:551–554.
   PubMed Web of Science ®Google Scholar
• Triponez F, Goudet P, Dosseh D, et al. French Endocrine Tumor Study Group. French Endocrine Tumor Study Group. Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg. 2006;30:654–662. discussion 663-4.
   PubMed Web of Science ®Google Scholar
• Triponez F, Sadowski SM, Pattou F, et al. Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small ≤2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: association Francophone de Chirurgie Endocrinienne & Groupe d’Etude des Tumeurs Endocrines. Ann Surg. 2018;268(1):158–164.
   PubMed Web of Science ®Google Scholar
• Christou N, Mathonnet M, Gaujoux S, et al. One-year postoperative mortality in MEN1 patients operated on gastric and duodenopancreatic neuroendocrine tumors: an AFCE and GTE cohort study. World J Surg. 2019;43(11):2856–2864.
   PubMed Web of Science ®Google Scholar
• Wolin EM. The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointest Cancer Res. 2012;5:161–168.
   PubMedGoogle Scholar
• Botsios D, Vasiliadis K, Tsalis K, et al. Management of nonfunctioning pancreatic endocrine tumors in the context of multiple endocrine neoplasia type 1 syndrome. J Gastrointestin Liver Dis. 2007;16(3):257–262.
   PubMed Web of Science ®Google Scholar
• Gulati AP, Krantz B, Moss RA, et al. Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature. Oncology. 2013;84(3):127–134.
   PubMed Web of Science ®Google Scholar
• Maia MC, Muniz Lourenço D Jr, Riechelmann R. Efficacy and Long-Term Safety of Everolimus in Pancreatic Neuroendocrine Tumor Associated with Multiple Endocrine Neoplasia Type I: case Report. Oncol Res Treat. 2016;39(10):643–645.
   PubMed Web of Science ®Google Scholar
• Nuñez JE, Donadio M, Filho DR, et al. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors. J Gastrointest Oncol. 2019;10(4):645–651.
   PubMed Web of Science ®Google Scholar
• Vergès B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002;87:457–465.
   PubMed Web of Science ®Google Scholar
• Livshits A, Kravarusic J, Chuang E, et al. Pituitary tumors in MEN1: do not be misled by borderline elevated prolactin levels. Pituitary. 2016;19:601–604.
   PubMed Web of Science ®Google Scholar
• Arafah BM, Prunty D, Ybarra J, et al. The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas. J Clin Endocrinol Metab. 2000;85:1789–1793.
   PubMed Web of Science ®Google Scholar
• Lim CT, Korbonits M. Update on the clinicopathology of pituitary adenomas. Endocr Pract. 2018;24(5):473–488.
   PubMed Web of Science ®Google Scholar
• de Laat JM, Pieterman CR, van den Broek MF, et al. Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients. J Clin Endocrinol Metab. 2014;99(9):3325–3333.
   PubMed Web of Science ®Google Scholar
• Lecomte P, Binquet C, Le Bras M, et al. Histologically proven bronchial neuroendocrine tumors in MEN1: a GTE 51-case cohort study. World J Surg. 2018;42(1):143–152.
   PubMed Web of Science ®Google Scholar
• Kamilaris CDC, Stratakis CA. Multiple endocrine neoplasia type 1 (MEN1): an update and the significance of early genetic and clinical diagnosis. Front Endocrinol (Lausanne). 2019;10:339.
   PubMed Web of Science ®Google Scholar
• van Leeuwaarde RS, Dreijerink KM, Ausems MG, et al. MEN1-Dependent Breast Cancer: indication for Early Screening? Results From the Dutch MEN1 Study Group. J Clin Endocrinol Metab. 2017;102(6):2083–2090.
   PubMed Web of Science ®Google Scholar
• Hill KA, Yip L, Carty SE, et al. Concomitant Thyroid Cancer in Patients with Multiple Endocrine Neoplasia Type 1 Undergoing Surgery for Primary Hyperparathyroidism. Thyroid. 2019;29(2):252–257.
   PubMed Web of Science ®Google Scholar
• Luzi E, Marini F, Giusti F, et al. The negative feedback-loop between the oncomir mir-24-1 and menin modulates the MEN1 tumorigenesis by mimicking the “Knudson’s second hit”. PLoS One. 2012;7(6):e39767.
   PubMed Web of Science ®Google Scholar
• Vijayaraghavan J, Maggi EC, Crabtree JS. miR-24 regulates menin in the endocrine pancreas. Am J Physiol Endocrinol Metab. 2014;307(1):E84–92.
   PubMed Web of Science ®Google Scholar
• Luzi E, Ciuffi S, Marini F, et al. Analysis of differentially expressed microRNAs in MEN1 parathyroid adenomas. Am J Transl Res. 2017;9(4):1743–1753.
   PubMed Web of Science ®Google Scholar
• Lines KE, Newey PJ, Yates CJ, et al. MiR-15a/miR-16-1 expression inversely correlates with cyclin D1 levels in MEN1 pituitary NETs. J Endocrinol. 2018;240(1):41–50.
   PubMed Web of Science ®Google Scholar